{
"id":"mk19_a_np_q106",
"number":106,
"bookId":"np",
"correctAnswer":"B",
"title":"Question 106",
"stimulus":[
{
"type":"p",
"hlId":"c9d37e",
"children":[
"A 46-year-old woman is evaluated during a follow-up visit for hypertension, type 2 diabetes mellitus, and stage G3 chronic kidney disease. She reports no symptoms. Medications are losartan, amlodipine, metformin, canagliflozin, and rosuvastatin."
]
},
{
"type":"p",
"hlId":"d31091",
"children":[
"On physical examination, blood pressure is 124/72 mm Hg. Other vital signs and the remainder of the examination are unremarkable."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"9d5fe2",
"children":[
"Laboratory studies: "
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"3a34ea",
"class":"cell text l",
"children":[
"1.6 mg/dL (141.4 Âµmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"89662a",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, serum",
"children":[
"Electrolytes"
]
},
":"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d41d8c",
"class":"cell text l",
"children":[

]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"b99276",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Sodium, serum",
"children":[
"Sodium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"1fd2c7",
"class":"cell text l",
"children":[
"136 mEq/L (136 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"e92687",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Potassium, serum",
"children":[
"Potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"af343e",
"class":"cell text l",
"children":[
"5.6 mEq/L (5.5 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"a207b1",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Chloride, serum",
"children":[
"Chloride"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"21724f",
"class":"cell text l",
"children":[
"104 mEq/L (104 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft2"
},
"children":[
{
"type":"p",
"hlId":"6827e3",
"class":"cell text li",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Electrolytes, Bicarbonate, serum",
"children":[
"Bicarbonate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"075484",
"class":"cell text l",
"children":[
"24 mEq/L (24 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"58e613",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Albumin-creatinine ratio, urine",
"children":[
"Urine albumin-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d7acf9",
"class":"cell text l",
"children":[
"320 mg/g"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"96ef5f",
"children":[
"ECG is normal."
]
},
{
"type":"p",
"hlId":"d867a5",
"children":[
"The patient is counseled to start a low potassium diet."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Add hydrochlorothiazide"
}
},
{
"letter":"B",
"text":{
"__html":"Add patiromer"
}
},
{
"letter":"C",
"text":{
"__html":"Administer intravenous calcium gluconate"
}
},
{
"letter":"D",
"text":{
"__html":"No further treatment"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"bdb9e7",
"children":[
"Potassium binders such as patiromer and sodium zirconium cyclosilicate can be used to treat hyperkalemia in patients with chronic kidney disease."
]
},
{
"type":"keypoint",
"hlId":"8a0137",
"children":[
"Use of potassium binders in patients with chronic kidney disease may allow continuation of essential medications, such as inhibitors of the renin-angiotensin system."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"187509",
"children":[
"The most appropriate management is to add patiromer (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"), a potassium binder, to treat this patient's moderate hyperkalemia. Initial evaluation of hyperkalemia requires a review of all medications, assessment of kidney function, and an ECG. Initial ECG manifestations include peaked precordial T waves and a shortened QT interval. Hyperkalemia frequently occurs in chronic kidney disease with an estimated glomerular filtration rate <20 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
". Hypoaldosteronism caused by inhibitors of the renin-angiotensin system, heparin, type 4 (hyperkalemic distal) renal tubular acidosis, or primary adrenal insufficiency also cause hyperkalemia. All potentially causative medications should be discontinued if possible. Although angiotensin receptor blockers (ARBs) such as losartan frequently cause hyperkalemia by decreasing aldosterone levels, guidelines recommend their use to slow the progression of kidney disease and provide cardiovascular protection. This patient has severely increased albuminuria, which puts her at increased risk for both progressing to end-stage kidney disease and a cardiovascular event. Routine discontinuation of ARBs has been associated with worsening outcomes; with the addition of effective potassium binders, discontinuation of ARBs is discouraged. Therefore, because of the beneficial cardiovascular and renal effects of blocking angiotensin, if serum potassium is only mildly elevated (as in this patient), the use of potassium binders may allow the patient to continue use of losartan. Patiromer and sodium zirconium cyclosilicate are two FDA-approved potassium binders. The choice of binder is determined by patient and physician preference, as each agent has its advantages and disadvantages. Sodium polystyrene sulfonate is no longer recommended as a potassium binder due to its poor efficacy in lowering potassium and numerous reported adverse effects."
]
},
{
"type":"p",
"hlId":"a35251",
"children":[
"Adding a thiazide diuretic such as hydrochlorothiazide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") may improve this patient's hyperkalemia. However, it could result in volume depletion with decreased delivery of sodium to the potassium secretory sites, resulting in worsening hyperkalemia. In addition, this patient's blood pressure is at goal and there is no indication to further lower it."
]
},
{
"type":"p",
"hlId":"b6f917",
"children":[
"When hyperkalemia is associated with changes on ECG, intravenous calcium gluconate (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") should be administered to stabilize the cardiac membrane by raising threshold potential. Because this patient's serum potassium was only moderately elevated and her ECG was normal, calcium gluconate is not indicated."
]
},
{
"type":"p",
"hlId":"80d1be",
"children":[
"Providing this patient with no treatment is inappropriate (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). Although her serum potassium is only moderately elevated, serum potassium levels >5 mEq/L (5 mmol/L) are associated with increased morbidity and mortality."
]
}
],
"relatedSection":"mk19_a_np_s2_3_2_2",
"objective":{
"__html":"Treat hyperkalemia."
},
"references":[
[
"Evans M, Palaka E, Furuland H, et al. The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease. BMC Nephrol. 2019;20:31. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30704421",
"target":"_blank"
},
"children":[
"PMID: 30704421"
]
},
" doi:10.1186/s12882-019-1228-y"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":14,
"B":29,
"C":4,
"D":53,
"E":0
},
"hlIds":[
"c9d37e",
"d31091",
"9d5fe2",
"f461b2",
"3a34ea",
"89662a",
"d41d8c",
"b99276",
"1fd2c7",
"e92687",
"af343e",
"a207b1",
"21724f",
"6827e3",
"075484",
"58e613",
"d7acf9",
"96ef5f",
"d867a5",
"cb2b54",
"bdb9e7",
"8a0137",
"187509",
"a35251",
"b6f917",
"80d1be"
]
}